cosentyx
novartis europharm limited - secukinumab - arthritis, psoriatic; psoriasis; spondylitis, ankylosing - imunosupresoare - plaque psoriasiscosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults and children from the age of 6 years old who are candidates for systemic therapy. hidradenitis suppurativa (hs)cosentyx is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic hs therapy. psoriazică arthritiscosentyx, singur sau în asociere cu metotrexat (mtx), este indicat pentru tratamentul artritei psoriazice active la pacienții adulți, atunci când răspunsul la precedenta modificare a bolii anti-reumatice droguri (marmb) a fost terapia inadecvată. spondilartrită axială (axspa)spondilita anchilozantă (ca, radiografic spondilartrită axială)cosentyx este indicat pentru tratamentul de spondilită anchilozantă activă la adulți care au răspuns inadecvat la terapia convențională. non-radiographic axial spondyloarthritis (nr-axspa)cosentyx is indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) evidence in adults who have responded inadequately to non steroidal anti inflammatory drugs (nsaids). juvenile idiopathic arthritis (jia)enthesitis-related arthritis (era)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active enthesitis-related arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy. juvenile psoriatic arthritis (jpsa)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active juvenile psoriatic arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.
dacogen
janssen-cilag international n.v. - decitabină - leucemie mieloidă - agenți antineoplazici - tratamentul pacienților adulți cu leucemie mieloidă acută de novo sau secundar nou diagnosticat (aml), conform clasificării organizației mondiale a sănătății (oms), care nu sunt candidați la chimioterapie standard de inducție.
ilumetri
almirall s.a - tildrakizumab - psoriazis - imunosupresoare, inhibitori de interleukină, - ilumetri este indicat pentru tratamentul adulților cu forme moderate sau severe de psoriazis în plăci la care sunt candidați pentru terapia sistemică.
jemperli
glaxosmithkline (ireland) limited - dostarlimab - endometrial neoplasms - antineoplastic agents and antibody drug conjugates - jemparli is indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dmmr)/microsatellite instability-high (msi h) recurrent or advanced endometrial cancer (ec) that has progressed on or following prior treatment with a platinum-containing regimen.
ceftriaxon pulbere pentru solutie injectabila 1 g
upm din borisov sad - pulbere pentru solutie injectabila - 1 g
octagam solutie perfuzabila 50 mg/ml
octapharma pharmazeutika produktionsges. m.b.h - immunoglobulinum umane - solutie perfuzabila - 50 mg/ml
octagam solutie perfuzabila 50 mg/ml
octapharma pharmazeutika produktionsges. m.b.h - immunoglobulinum umane - solutie perfuzabila - 50 mg/ml
octagam solutie perfuzabila 50 mg/ml
octapharma pharmazeutika produktionsges. m.b.h - immunoglobulinum umane - solutie perfuzabila - 50 mg/ml
octagam solutie perfuzabila 50 mg/ml
octapharma pharmazeutika produktionsges. m.b.h - immunoglobulinum umane - solutie perfuzabila - 50 mg/ml
peo cu lidocaina pulbere si solvent pentru solutie injectabila 1 g
gm pharmaceuticals ltd. - ceftriaxonum - pulbere si solvent pentru solutie injectabila - 1 g